Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial
…, N Cordua, A Santoro, G Giaccone, TM De Pas - The Lancet …, 2022 - thelancet.com
Background Patients with advanced type B3 thymoma and thymic carcinoma resistant to
chemotherapy have few treatment options. We report the efficacy and safety results of the …
chemotherapy have few treatment options. We report the efficacy and safety results of the …
[HTML][HTML] Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with or without adjuvant chemotherapy in patients with resected stage IB to III MAGE-A3 …
JL Pujol, JF Vansteenkiste, TM De Pas… - Journal of Thoracic …, 2015 - Elsevier
Introduction To assess the safety and immunogenicity of MAGE-A3 immunotherapeutic in
patients with stage IB–III MAGE-A3-positive non–small-cell lung cancer (NSCLC) who were or …
patients with stage IB–III MAGE-A3-positive non–small-cell lung cancer (NSCLC) who were or …
Stem cell transplantation effectively occludes bronchopleural fistula in an animal model
F Petrella, F Toffalorio, S Brizzola, TM De Pas… - The Annals of thoracic …, 2014 - Elsevier
Background Bronchopleural fistula after lung resection still represents a challenging life-threatening
complication for thoracic surgeons. Considering its extremely high mortality rate, an …
complication for thoracic surgeons. Considering its extremely high mortality rate, an …
The activity of chemotherapy in inflammatory myofibroblastic tumors: a multicenter, European retrospective case series analysis
…, O Mir, M Casanova, B Vincenzi, TM De Pas… - The …, 2020 - academic.oup.com
Background This study aimed to review the activity of cytotoxic chemotherapy in patients
with inflammatory myofibroblastic tumors (IMTs) treated at nine European sarcoma reference …
with inflammatory myofibroblastic tumors (IMTs) treated at nine European sarcoma reference …
EGFR tyrosine kinase inhibitors beyond focal progression obtain a prolonged disease control in patients with advanced adenocarcinoma of the lung
…, A Delmonte, M Santarpia, C Lazzari, TM De Pas - Lung Cancer, 2013 - Elsevier
Introduction Recent data show that EGFR pathway and its inhibition maintain their role after
progression of disease during EGFR TKI therapy in NSCLCs. We conducted a retrospective …
progression of disease during EGFR TKI therapy in NSCLCs. We conducted a retrospective …
Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer
In mammalian cells, the process of malignant transformation is characterized by the loss or
down-regulation of tumor-suppressor genes and/or the mutation or overexpression of proto-…
down-regulation of tumor-suppressor genes and/or the mutation or overexpression of proto-…
[HTML][HTML] Phase II trial of neoadjuvant pemetrexed plus cisplatin followed by surgery and radiation in the treatment of pleural mesothelioma
…, F Adolfo, M Giuseppe, S Lorenzo, DPT Martino… - BMC cancer, 2013 - Springer
Background Malignant pleural mesothelioma is an aggressive tumor that has a poor prognosis
and is resistant to unimodal approaches. Multimodal treatment has provided encouraging …
and is resistant to unimodal approaches. Multimodal treatment has provided encouraging …
Guideline-Based Follow-Up Outcomes in Patients With Gastrointestinal Stromal Tumor With Low Risk of Recurrence: A Report From the Italian Sarcoma Group
L D'Ambrosio, E Fumagalli, TM De Pas… - JAMA Network …, 2023 - jamanetwork.com
Importance Gastrointestinal stromal tumor (GIST) follow-up is recommended by international
guidelines, but data on the role of follow-up in patients with low relapse risk are missing. For …
guidelines, but data on the role of follow-up in patients with low relapse risk are missing. For …
Targeting ALK in patients with advanced non small cell lung cancer: biology, diagnostic and therapeutic options
…, A Delmonte, F Toffalorio, F Conforti, TM De Pas - Critical reviews in …, 2014 - Elsevier
The discovery of EML4-ALK fusion gene in a subgroup of patients with lung adenocarcinoma
led to the development of a new class of agents, the ALK inhibitors, and dramatically …
led to the development of a new class of agents, the ALK inhibitors, and dramatically …
First-in-human phase I study of the ALK inhibitor LDK378 in advanced solid tumors.
…, E Felip, DSW Tan, JF Vansteenkiste, TM De Pas… - 2012 - ascopubs.org
3007 Background: LDK378 is a novel, potent and selective small molecule anaplastic
lymphoma kinase (ALK) inhibitor (IC 50 0.00015 μM), that does not inhibit c-MET (IC 50 3.2 μM). …
lymphoma kinase (ALK) inhibitor (IC 50 0.00015 μM), that does not inhibit c-MET (IC 50 3.2 μM). …